CClinicalTrials.gg
Active, not recruitingNCT03423953Updated Apr 21, 2026

Comprehensive Nano - Post Market Clinical Follow-Up Study

An observational study in Osteoarthritis, Avascular Necrosis and Rheumatoid Arthritis, sponsored by Zimmer Biomet. Active, not recruiting at 5 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-21.

Sponsored by Zimmer Biomet · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
194
Ages
18 Years and older
Sex
All
01

Study summary

This data collection project is intended to provide clinical outcomes data to engineering, marketing as well as fulfill the post market surveillance requirements of various regulatory authorities. The study will be a prospective and one-arm.

Read the detailed description

The Comprehensive® Shoulder System with Nano humeral component is a humeral prosthesis system intended for use in total or hemi shoulder arthroplasty surgery. Total shoulder arthroplasty consists of replacement of the humeral head and glenoid. Hemi-arthroplasty consists of replacement of only the humeral head.

This project is a prospective study including one-hundred and fifty (150) anatomic and hemi cases and 44 reverse shoulders collected from up to ten (10) sites. All potential study subjects will be required to participate in the Informed Consent process.

02

Conditions studied

  • Osteoarthritis
  • Avascular Necrosis
  • Rheumatoid Arthritis
  • Revision
  • Correction of Functional Deformity

Keywords

  • osteoarthritis
  • avascular necrosis
  • rheumatoid arthritis
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Patients in need of an uncemented shoulder arthroplasty and who meet all of the inclusion and none of the exclusion criteria.

Inclusion criteria

  • Non-inflammatory degenerative joint disease including osteoarthritis and avascular necrosis.
  • Rheumatoid arthritis
  • Revision where other devices or treatments have failed
  • Correction of functional deformity.
  • Difficult clinical management problems where other methods of treatment may not be suitable or may be inadequate
  • Difficult clinical management problems where other methods of treatment may not be suitable or may be inadequate

Exclusion criteria

Exclusion Criteria:

  • Infection
  • Sepsis
  • osteomyelitis
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
194 participants (estimated)
Patient registry
No

Groups and cohorts

  • Anatomic

    Patients receiving the Anatomic or Hemi verison of the Comprehensive Nano.

    Device: Comprehensive Nano

  • Reverse

    Patients who have received the Reverse version of the Comprehensive Nano.

    Device: Comprehensive Nano

Interventions

  • DeviceComprehensive Nano

    Patients requiring the Comprehensive Nano shoulder system.

05

What researchers measure

Primary outcomes

  1. Survivorship

    Kaplan Meier method

    Time frame: 10 years

Secondary outcomes

  1. ASES Score (American Shoulder and Elbow Surgeons)

    Improvement in this score from preop to 10 year follow-up. This score includes 2 scales: 1 scale for pain, from 0 to 10 where 0 stands for "no pain at all" and 10 for "pain as bad as it can be". The second scale is for the stability of the shoulder, from 0 to 10 (0 stands for "very stable" and 10 for "very unstable").

    Time frame: 10 years

  2. SANE Score (Single Assessment Numeric Evaluation)

    Improvement in this score from preop to 10 year follow-up. This is a simple, single-question, patient-based shoulder function assessment tool: "How would you rate your shoulder today as a percentage of normal (0% to 100% scale with 100% being normal)?"

    Time frame: 10 years

  3. Constant-Murley Score

    Improvement in this score from preop to 10 year follow-up. This is a 100-point score. Higher scores indicate a better outcome.

    Time frame: 10 years

  4. X-rays evaluated for radiolucencies, osteolysis, migration and subsidence

    Standard evaluation performed on both humeral and glenoid components

    Time frame: 10 years

06

Study locations

5 sites
  • Privatklinik Leech
    Graz, Styria 8010, Austria
  • Kingston General Hospital
    Kingston, Ontario K7L 3N6, Canada
  • Chonnam National University Hospital
    Gwangju, Gwangju, South Korea
  • Samsung Medical Centre
    Seoul, Seoul 06351, South Korea
  • University of Liverpool
    Liverpool, Merseyside L69 3BX, United Kingdom
07

Registry details

Key details

Study ID
NCT03423953
Lead sponsor
Zimmer Biomet
Responsible party
Sponsor
First posted
Feb 6, 2018
Start date
Oct 30, 2013
Primary completion
Jul 31, 2030 (estimated)
Completion
Jul 31, 2030 (estimated)
Last update
Apr 21, 2026

Study contacts

Paola Vivoda
study director · Zimmer Biomet

Oversight

FDA-regulated drug
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion